University of Cagliari
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure
Prisco, Domenico;Barcellona, Doris;
2021-01-01
Abstract
Trial of Rivaroxaban in AntiPhospholipid Syndrome was a prospective randomized, open-label, noninferiority study conducted in 14 centers in Italy. Rivaroxaban was compared with warfarin for the prevention of thromboembolic events, major bleeding, and vascular death in high-risk, triple-positive patients with antiphospholipid syndrome.
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| 2020 JTH (1).pdf Solo gestori archivio
Type: versione post-print
Size 5.92 MB
Format Adobe PDF
|
5.92 MB | Adobe PDF | & nbsp; View / Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.